G007-LK Tankyrase 1/2 Inhibitor: Mechanism, Evidence & Applications

Executive Summary: G007-LK is a small-molecule inhibitor that specifically targets tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), suppressing poly(ADP-ribosyl)ation activity with nanomolar potency (IC₅₀ = 46 nM for TNKS1, 25 nM for TNKS2) (APExBIO). It blocks Wnt/β-catenin signaling in cell lines and animal models, causing β-catenin degradation and AXIN1/2 stabilization (Jia et al., 2017). G007-LK demonstrates antitumor activity in APC-mutant colorectal cancer and hepatocellular carcinoma models. It is highly soluble in DMSO (≥26.5 mg/mL), but insoluble in water and ethanol, requiring specific handling for experimental use. The compound is widely adopted in research for dissecting canonical Wnt and Hippo pathway mechanisms in cancer biology.

Biological Rationale

Tankyrases, including TNKS1 and TNKS2, are enzymes within the poly(ADP-ribose) polymerase (PARP) family. They regulate diverse cellular processes such as telomere maintenance, Wnt/β-catenin signaling, and cell cycle progression (Jia et al., 2017). Aberrant tankyrase activity is linked to various cancers, notably colorectal cancer with APC mutations and hepatocellular carcinoma. Elevated TNKS1/2 levels are found in tumor tissues, correlating with enhanced β-catenin signaling and poor prognosis. Inhibition of tankyrases disrupts the degradation of AXIN1/2, causing destabilization of β-catenin and attenuation of Wnt-driven transcriptional programs. This mechanism underpins the rationale for tankyrase inhibitors as research tools and potential therapeutics.

For a comprehensive mechanistic overview, see the analysis in Redefining Oncogenic Pathway Targeting; this article specifically updates the experimental and practical aspects for G007-LK in cellular and in vivo systems.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK selectively binds to the catalytic PARP domain of TNKS1/2, inhibiting their auto-poly(ADP-ribosyl)ation activity. This inhibition is quantified by IC₅₀ values of 46 nM for TNKS1 and 25 nM for TNKS2 in biochemical assays (APExBIO). In cell-based models, such as Wnt3a-induced HEK 293 cells, G007-LK suppresses Wnt signaling reporter activity (ST-Luc) with an IC₅₀ of 0.05 μM. In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK induces assembly of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, promoting β-catenin degradation and reducing its cytosolic and nuclear levels. The stabilization of AXIN1/2 further amplifies the β-catenin destruction complex, resulting in pronounced Wnt pathway inhibition (Jia et al., 2017).

Notably, G007-LK also affects the Hippo pathway by downregulating YAP/TAZ activity, partially via stabilization of AMOTL1 and AMOTL2—negative regulators of YAP nuclear translocation.

Evidence & Benchmarks

• G007-LK inhibits tankyrase 1 and 2 enzymatic activity with IC₅₀ values of 46 nM and 25 nM, respectively (APExBIO).
• In Wnt3a-induced HEK 293 reporter assays, G007-LK achieves an IC₅₀ of 0.05 μM for ST-Luc inhibition (APExBIO).
• In SW480 (APC-mutant) colorectal cancer cells, G007-LK induces degradasome formation and decreases cytosolic/nuclear β-catenin (APExBIO).
• In COLO-320DM xenograft mouse models, G007-LK reduces tumor growth and TNKS1/2, β-catenin protein levels, while stabilizing AXIN1/2 (APExBIO).
• Tankyrase inhibitors, including G007-LK, suppress hepatocellular carcinoma cell proliferation and YAP activity by stabilizing AMOTL1/2 (Jia et al., 2017, DOI).
• G007-LK demonstrates synergy when combined with MEK and AKT inhibitors in in vitro HCC models (Jia et al., 2017, DOI).
• For practical tips on solubility and assay setup, see G007-LK Tankyrase 1/2 Inhibitor (SKU B5830): Practical Solutions; this article extends those protocols with updated evidence and mechanistic context.

Applications, Limits & Misconceptions

G007-LK is primarily used for research on:

• Wnt/β-catenin pathway inhibition in APC-mutant colorectal cancer, hepatocellular carcinoma, and other cancers.
• β-catenin degradation and AXIN1/2 stabilization studies.
• Hippo pathway modulation via YAP/TAZ downregulation and AMOTL1/2 stabilization.
• Synergy assessment with pathway inhibitors (e.g., MEK, AKT).

Limitations include:

• Not suitable for direct clinical application; for research use only (RUO).
• Effectiveness is cell-context dependent; not all Wnt-driven cancers respond equally.
• Requires DMSO for solubilization; insoluble in water and ethanol.
• Long-term storage of solutions is not advised; store as solid at -20°C (APExBIO).

Common Pitfalls or Misconceptions

• G007-LK is not a pan-PARP inhibitor; activity is selective for tankyrase 1 and 2.
• It is not effective in models where Wnt/β-catenin signaling is not the primary driver of tumorigenesis.
• Not intended for in vivo therapeutic use in humans; preclinical only.
• Improper solubilization (using water or ethanol) results in precipitation and unreliable dosing.
• Effects on YAP/TAZ are indirect and rely on AMOTL1/2 context; not all YAP-driven cancers will respond.

For further pitfalls and lab-specific troubleshooting, see Solving Lab Challenges with G007-LK Tankyrase 1/2 Inhibitor; this article clarifies mechanistic boundaries and application limits not fully addressed elsewhere.

Workflow Integration & Parameters

• Preparation: Dissolve G007-LK in DMSO at ≥26.5 mg/mL. Warm to 37°C or sonicate if necessary. Do not use water or ethanol as solvents (APExBIO).
• Storage: Store solid at -20°C. Avoid long-term storage of solutions.
• Recommended concentrations: For cell-based Wnt/β-catenin assays, start with 0.01–1 μM. For in vivo studies, refer to published protocols (Jia et al., 2017).
• Controls: Include DMSO vehicle and positive/negative pathway controls for each assay.
• Assay readouts: Use ST-Luc reporter, β-catenin Western blot, and AXIN1/2 quantification for pathway validation.

This workflow supplements and updates the method-focused guidance in G007-LK: Advanced Tankyrase Inhibitor for β-Catenin and Hippo Pathways, integrating newer benchmarks and storage parameters.

Conclusion & Outlook

G007-LK, available from APExBIO, is a benchmark tankyrase 1/2 inhibitor for dissecting Wnt/β-catenin and Hippo pathway mechanisms in preclinical research. Its high potency, selectivity, and robust performance in APC-mutant and hepatocellular carcinoma models make it a preferred tool for pathway-targeted studies. Continued research will clarify its utility in combination regimens and additional cancer types. For detailed product specifications, protocols, and ordering, refer to the official G007-LK tankyrase 1/2 inhibitor page.